You searched for "therapeutics"
DALK as an early therapeutic option for Acanthamoeba keratitis
Eleven patients with Acanthamoeba keratitis (AK) were treated by early therapeutic deep anterior lamellar keratoplasty (DALK). All surgeries were performed in patients who had no response to standard medical therapy of chlorhexidine gluconate, propamidine isethionate and neomycin sulphate, within 10-15...
Ranibizumab for the treatment of age-related macular degeneration
This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...
Pilot trial of virtual reality to treat amblyopia beyond the age of seven years
A pilot double-blind randomised controlled trial is presented. Patients were required to be between seven and 38 years of age, have a diagnosis of anisometropic and / or strabismus unilateral amblyopia, visual acuity in the amblyopic eye between 0.3-1.0 LogMAR...
Detecting apoptosis in retinal cells
This is a review paper in which the authors summarise the transitioning of techniques detecting apoptosis from bench to bedside, along with the future possibilities they encase. Detection of Apoptosis in Retinal Cells (DARC) technology can be used as a...My Top Five: Promising gene therapies for ocular conditions
Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...My Top Five: Promising gene therapies for ocular conditions
Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...
Insights in resistant diabetic macular oedema
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...The expanding role of the optometrist
Eyecare in the UK has seen significant changes in recent years, with new models of care, technological advancements and an increased emphasis on primary eyecare in some UK nations. Crucially, an ageing population demographic is set to escalate further both...In conversation with Robert MacLaren
Professor Robert MacLaren gave the Keeler Lecture at the Royal College of Ophthalmologists Annual Meeting in May 2019 on gene therapy for retinitis pigmentosa. We caught up with him afterwards to find out more. What are the key messages of...Renewed momentum in ocular gene and cell therapy, broadening application to chronic disease
Gene and cell therapies offer the prospect of ground-breaking new avenues for the treatment of diseases, reflected in a renewed explosion of interest and investment in retinal gene therapy. Rod McNeil reports recent clinical trial readouts across a diverse range...
